Company research
Lyra Therapeutics, Inc.
CIK 1327273Updated Oct 6, 2026
Historical securities (1)
LYRA · NASDAQ · equity · closed Mar 16, 2026LYRA price & chart
Loading TradingView…
OTC:LYRA on TradingView ↗About the company
We are a clinical-stage biotechnology company focused on the development and commercialization of innovative, anti-inflammatory therapies for the localized treatment of patients with chronic rhinosinusitis, or CRS. CRS is an inflammatory disease of the paranasal sinuses which leads to debilitating symptoms and significant morbidities and affects approximately 14 million people in the United States. Our primary product candidate, LYR-210, is a bioabsorbable nasal insert designed to be administered in a simple, in-office procedure and intended to deliver six months of continuous anti-inflammatory drug therapy to the sinonasal passages for the treatment of CRS with a single administration. The drug embedded within LYR-210 is mometasone furoate, or MF, which is the active ingredient in various U.S. Food and Drug Administration, or FDA, approved drugs and has a well-established efficacy and safety profile.
In the news
No coverage from other publishers is available.
Recent filings
4 filing
15-12G filing
25 filing
Termination of a Material Definitive Agreement
Items 1.02
Termination of a Material Definitive Agreement
Items 1.02
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q3 2023 | Q2 2025 | Q2 2024 | Q2 2023 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 43,709,000Source | 78,756,000Source | 120,575,000Source | 52,573,000Source | 94,582,000Source | 125,675,000Source | 56,316,000Source | 141,527,000Source | 36,108,000Source | 66,346,000Source | 142,600,000Source | 109,968,000Source |
| Property, Plant and Equipment, NetUSD | 1,122,000Source | 1,613,000Source | 726,000Source | 1,159,000Source | 1,665,000Source | 560,000Source | 1,276,000Source | 3,783,000Source | 1,051,000Source | 1,404,000Source | 2,043,000Source | 2,243,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 22,055,000Source | 23,800,000Source | 24,850,000Source | 29,784,000Source | 31,905,000Source | 54,361,000Source | 31,735,000Source | 15,799,000Source | 15,893,000Source | 40,577,000Source | 22,353,000Source | 32,550,000Source |
| Assets, CurrentUSD | 23,019,000Source | 54,444,000Source | 104,920,000Source | 31,063,000Source | 69,435,000Source | 118,253,000Source | 33,905,000Source | 89,443,000Source | 16,272,000Source | 43,025,000Source | 104,821,000Source | 100,829,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 964,000Source | 2,818,000Source | 2,370,000Source | 1,279,000Source | 1,937,000Source | 1,800,000Source | 2,170,000Source | 2,325,000Source | 379,000Source | 2,448,000Source | 2,068,000Source | 2,935,000Source |
| Operating Lease, Right-of-Use AssetUSD | 17,575,000Source | 20,707,000Source | 6,074,000Source | 18,358,000Source | 21,490,000Source | 1,420,000Source | 19,142,000Source | 45,626,000Source | 16,792,000Source | 19,924,000Source | 33,233,000Source | 2,223,000Source |
| Other Assets, NoncurrentUSD | — | — | 7,463,000Source | — | — | 4,353,000Source | — | 683,000Source | — | 0Source | 1,111,000Source | 3,281,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 48,037,000Source | 58,137,000Source | 36,336,000Source | 50,951,000Source | 63,605,000Source | 27,098,000Source | 52,444,000Source | 64,023,000Source | 46,825,000Source | 54,752,000Source | 53,180,000Source | 29,214,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 2,000Source | 65,000Source | 50,000Source | 2,000Source | 65,000Source | 50,000Source | 66,000Source | 61,000Source | 2,000Source | 65,000Source | 57,000Source | 32,000Source |
| Retained Earnings (Accumulated Deficit)USD | -426,758,000Source | -393,811,000Source | -296,199,000Source | -420,774,000Source | -381,938,000Source | -280,548,000Source | -413,337,000Source | -333,807,000Source | -433,709,000Source | -404,790,000Source | -311,355,000Source | -248,675,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | 20,000Source | -7,000Source | — | -4,000Source | -27,000Source | — | 25,000Source | — | 0Source | 33,000Source | 10,000Source |
| Stockholders' Equity Attributable to ParentUSD | -4,328,000Source | 20,619,000Source | 84,239,000Source | 1,622,000Source | 30,973,000Source | 98,577,000Source | 3,872,000Source | 77,504,000Source | -10,717,000Source | 11,594,000Source | 89,420,000Source | 80,754,000Source |
| Additional Paid in Capital, Common StockUSD | 422,428,000Source | 414,345,000Source | 380,395,000Source | 422,394,000Source | 412,854,000Source | 379,102,000Source | 417,143,000Source | 411,225,000Source | 422,990,000Source | 416,319,000Source | 400,685,000Source | 329,387,000Source |
| Liabilities and EquityUSD | 43,709,000Source | 78,756,000Source | 120,575,000Source | 52,573,000Source | 94,582,000Source | 125,675,000Source | 56,316,000Source | 141,527,000Source | 36,108,000Source | 66,346,000Source | 142,600,000Source | 109,968,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 9,480,000Source | 14,954,000Source | 19,235,000Source | 11,163,000Source | 19,276,000Source | 14,111,000Source | 11,470,000Source | 18,724,000Source | 9,522,000Source | 12,631,000Source | 19,597,000Source | 14,470,000Source |
| Operating Lease, Liability, CurrentUSD | 4,684,000Source | 4,003,000Source | 1,403,000Source | 4,552,000Source | 4,269,000Source | 1,688,000Source | 4,243,000Source | 4,504,000Source | 4,818,000Source | 4,121,000Source | 5,434,000Source | 1,549,000Source |
| Accounts Payable, CurrentUSD | 627,000Source | 2,292,000Source | 5,054,000Source | 680,000Source | 4,971,000Source | 4,188,000Source | 725,000Source | 2,844,000Source | 663,000Source | 1,179,000Source | 3,131,000Source | 2,616,000Source |
| Operating Lease, Liability, NoncurrentUSD | 26,695,000Source | 31,321,000Source | 4,887,000Source | 27,926,000Source | 32,479,000Source | — | 29,113,000Source | 33,356,000Source | 25,441,000Source | 30,259,000Source | 21,447,000Source | 667,000Source |
| Additional Financial Items | ||||||||||||
| Deferred Revenue, CurrentUSD | 7,000Source | 607,000Source | 1,726,000Source | 32,000Source | 814,000Source | 1,497,000Source | 216,000Source | 1,319,000Source | — | 398,000Source | 1,658,000Source | 1,275,000Source |
| Deferred Revenue, NoncurrentUSD | 11,862,000Source | 11,862,000Source | 12,214,000Source | 11,862,000Source | 11,850,000Source | 12,987,000Source | 11,861,000Source | 11,943,000Source | 11,862,000Source | 11,862,000Source | 12,136,000Source | 14,077,000Source |
| Short-term InvestmentsUSD | — | 27,826,000Source | 77,700,000Source | — | 35,593,000Source | 61,789,000Source | — | 71,319,000Source | 0Source | 0Source | 80,400,000Source | 65,344,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2025 | Q2 2024 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -8,547,000Source | -22,452,000Source | -28,919,000Source | -93,435,000Source | -62,680,000Source | -55,278,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 825,000Source | 2,162,000Source | 2,335,000Source | 6,716,000Source | 5,887,000Source | 5,447,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -454,000Source | -560,000Source | -516,000Source | -1,887,000Source | 450,000Source | -2,411,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -8,842,000Source | -22,455,000Source | -28,859,000Source | -70,011,000Source | -63,304,000Source | -43,385,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | 7,857,000Source | -98,000Source | 80,305,000Source | -12,584,000Source | -65,006,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | 2,149,000Source | 116,000Source | 2,338,000Source | 1,047,000Source | 164,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | — | 8,644,000Source | 4,273,000Source | 8,531,000Source | 65,691,000Source | 96,257,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -8,842,000Source | -5,954,000Source | -24,684,000Source | 18,825,000Source | -10,197,000Source | -12,134,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 24,048,000Source | 25,792,000Source | 31,777,000Source | 33,897,000Source | 33,728,000Source | 17,791,000Source | 17,886,000Source | 42,570,000Source | 23,745,000Source | 33,942,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 34,000Source | 1,491,000Source | 914,000Source | 1,124,000Source | 825,000Source | 2,162,000Source | 2,335,000Source | 6,716,000Source | 5,887,000Source | 5,447,000Source |
| DepreciationUSD | — | — | 100,000Source | — | 200,000Source | 200,000Source | 128,000Source | 136,000Source | 459,000Source | 471,000Source | 278,000Source | 1,067,000Source |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | — | — | — | — | — | — | — | — | 8,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 2,236,000Source | 3,931,000Source | 3,501,000Source | 5,139,000Source | 3,263,000Source | 5,818,000Source | 11,540,000Source | 18,501,000Source | 19,057,000Source | 17,556,000Source |
| Income Tax Expense (Benefit)USD | — | — | 3,000Source | 7,000Source | 2,000Source | 12,000Source | 4,000Source | 14,000Source | 11,000Source | 39,000Source | 59,000Source | 13,000Source |
| Investment Income, InterestUSD | — | — | 256,000Source | 576,000Source | 410,000Source | 855,000Source | 298,000Source | 1,086,000Source | 1,133,000Source | 2,952,000Source | 4,499,000Source | 1,041,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -5,984,000Source | -11,873,000Source | -7,437,000Source | -48,131,000Source | -8,547,000Source | -22,452,000Source | -28,919,000Source | -93,435,000Source | -62,680,000Source | -55,278,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | -28,919,000Source | -93,435,000Source | -62,680,000Source | -55,278,000Source |
| Nonoperating Income (Expense)USD | — | — | 256,000Source | 576,000Source | 1,391,000Source | 855,000Source | 298,000Source | 1,086,000Source | 2,114,000Source | 2,952,000Source | 4,499,000Source | 1,041,000Source |
| Operating ExpensesUSD | — | — | 6,262,000Source | 12,637,000Source | 9,009,000Source | 49,572,000Source | 9,024,000Source | 24,056,000Source | 31,420,000Source | 97,882,000Source | 68,678,000Source | 57,669,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | 5,100,000Source | 6,400,000Source | 2,000,000Source | 1,100,000Source |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | — | 20,525,000Source | — | 47,949,000Source | 122,423,000Source | 64,842,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | — | — | — | — | — | — | — | 30,531,000Source | — | 130,592,000Source | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | 3,000Source | — | 3,000Source | 103,000Source | 8,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2025 | Q2 2024 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 25,000Source | 195,000Source | 183,000Source | 598,000Source | 183,000Source | 532,000Source | 398,000Source | 1,534,000Source | 1,558,000Source | 1,363,000Source |
| Operating Income (Loss)USD | — | — | -6,237,000Source | -12,442,000Source | -8,826,000Source | -48,974,000Source | -8,841,000Source | -23,524,000Source | -31,022,000Source | -96,348,000Source | -67,120,000Source | -56,306,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -5,981,000Source | -11,866,000Source | -7,435,000Source | -48,119,000Source | -8,543,000Source | -22,438,000Source | -28,908,000Source | -93,396,000Source | -62,621,000Source | -55,265,000Source |
| Income Tax Expense (Benefit)USD | — | — | 3,000Source | 7,000Source | 2,000Source | 12,000Source | 4,000Source | 14,000Source | 11,000Source | 39,000Source | 59,000Source | 13,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -5,984,000Source | -11,873,000Source | -7,437,000Source | -48,131,000Source | -8,547,000Source | -22,452,000Source | -28,919,000Source | -93,435,000Source | -62,680,000Source | -55,278,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -3.38Source | -9.07Source | -5.51Source | -36.76Source | -0.13Source | -0.35Source | -18.62Source | -1.43Source | -1.26Source | -1.83Source |
| Earnings Per Share, DilutedUSD per share | — | — | -3.38Source | -9.07Source | -5.51Source | -36.76Source | -0.13Source | -0.35Source | -18.62Source | -1.43Source | -1.26Source | -1.83Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 1,767,814Source | 1,309,134Source | 1,348,630Source | 1,309,193Source | 65,757,860Source | 64,011,360Source | 1,553,473Source | 65,113,859Source | 49,804,283Source | 30,235,689Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 1,767,814Source | 1,309,134Source | 1,348,630Source | 1,309,193Source | 65,757,860Source | 64,011,360Source | 1,553,473Source | 65,113,859Source | 49,804,283Source | 30,235,689Source |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 2,236,000Source | 3,931,000Source | 3,501,000Source | 5,139,000Source | 3,263,000Source | 5,818,000Source | 11,540,000Source | 18,501,000Source | 19,057,000Source | 17,556,000Source |
| Investment Income, InterestUSD | — | — | 256,000Source | 576,000Source | 410,000Source | 855,000Source | 298,000Source | 1,086,000Source | 1,133,000Source | 2,952,000Source | 4,499,000Source | 1,041,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | -28,919,000Source | -93,435,000Source | -62,680,000Source | -55,278,000Source |
| Nonoperating Income (Expense)USD | — | — | 256,000Source | 576,000Source | 1,391,000Source | 855,000Source | 298,000Source | 1,086,000Source | 2,114,000Source | 2,952,000Source | 4,499,000Source | 1,041,000Source |
| Operating ExpensesUSD | — | — | 6,262,000Source | 12,637,000Source | 9,009,000Source | 49,572,000Source | 9,024,000Source | 24,056,000Source | 31,420,000Source | 97,882,000Source | 68,678,000Source | 57,669,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | 5,100,000Source | 6,400,000Source | 2,000,000Source | 1,100,000Source |
| Other IncomeUSD | — | — | 0Source | 0Source | 981,000Source | 0Source | — | — | 981,000Source | — | — | — |
| Research and Development ExpenseUSD | — | — | 4,047,000Source | 5,902,000Source | 5,110,000Source | 13,264,000Source | 4,876,000Source | 18,238,000Source | 18,411,000Source | 43,766,000Source | 48,029,000Source | 38,797,000Source |
| Restructuring and Related Cost, Incurred CostUSD | — | — | — | 2,800,000Source | — | 6,500,000Source | — | — | 1,500,000Source | 10,900,000Source | — | — |
Offerings
Registration 333-264864
Registration 333-272981
Registration 333-278163
Registration 333-288872
Filing attachments
lyra-ex99_1.htm · 8-K · 2025-11-12
EX-99.1 2 lyra-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Company plans new, confirmatory Phase 3 clinical trial of LYR-210 for treatment of chronic rhinosinusitis (CRS) without nasal polyps, on path to NDA submission - WATERTOWN, Mass., November 12, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-act…
Read attachment ↗d71675dex991.htm · 8-K · 2025-09-04
EX-99.1 2 d71675dex991.htm EX-99.1 EX-99.1 Investor Presentation September 2025 Exhibit 99.1 Forward Looking Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” and similar expressions are intended to identify forward-looking statements. All statements contained in this presentation that do not relate to matter…
Read attachment ↗lyra-ex99_1.htm · 8-K · 2025-08-12
EX-99.1 2 lyra-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Positive ENLIGHTEN 2 Phase 3 results announced in June 2025 propel business activities in manufacturing, regulatory strategy and ENLIGHTEN clinical dataset analysis to advance path forward for LYR-210 for treatment of chronic rhinosinusitis (CRS) - - Financing announced in June 2025 extends cash runway into 3Q 2026 - WATERTOWN, Mass., Aug…
Read attachment ↗lyra-ex99_2.htm · 8-K · 2025-08-12
EX-99.2 3 lyra-ex99_2.htm EX-99.2 Investor Presentation August 2025 Forward Looking Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” and similar expressions are intended to identify forward-looking statements. All statements contained in this presentation that do not relate to matters of historical fact shoul…
Read attachment ↗d75821dex41.htm · 8-K · 2025-06-27
EX-4.1 2 d75821dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT LYRA THERAPEUTICS, INC. Warrant Shares: _______ Initial Exercise Date: June 27, 2025 Issue Date: June 27, 2025 ───────────────────────────────────────────────────────────────────── THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subje…
Read attachment ↗d75821dex42.htm · 8-K · 2025-06-27
EX-4.2 3 d75821dex42.htm EX-4.2 EX-4.2 Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO…
Read attachment ↗